SFCM
RLMD icon

Seven Fleet Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Seven Fleet Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-154,109
Closed -$744K – 134
2025
Q4 		$744K Buy
+154,109
New +$516K 0.5% 38

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Seven Fleet Capital Management's RLMD Position: Q1 2026 in Review

Seven Fleet Capital Management sold out of Relmada Therapeutics (RLMD) in Q1 2026, closing a stake of 154,109 shares — an estimated $744K sold.

Seven Fleet Capital Management first reported a position in RLMD in Q4 2025 and held it in 1 quarter. The position peaked at $744K in Q4 2025. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Seven Fleet Capital Management reported no remaining Relmada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Seven Fleet Capital Management sold 154,109 Relmada Therapeutics shares in Q1 2026, an estimated $744K.
  • Seven Fleet Capital Management first reported a position in Relmada Therapeutics in Q4 2025 and held it in 1 quarter.
  • Seven Fleet Capital Management's Relmada Therapeutics position peaked at $744K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.